Company Insights

PHGE supplier relationships

Explore interactive graphBrowse insights index
PHGE supplier relationship map

BiomX (PHGE) — supplier relationships, funding partners, and operational constraints investors need to know

BiomX is a clinical-stage microbiome and phage-therapy developer that monetizes through a mix of non-dilutive government grants and awards, licensing activity, and capital markets transactions (private placements and at‑the‑market equity programs) to fund R&D until product revenues materialize. The firm has zero reported revenues and relies on external funding and third‑party manufacturing and services to advance clinical programs; investor returns will hinge on successful regulatory progress or strategic partnerships that convert scientific assets into commercial receipts. For a quick corporate view and supplier signals, visit https://nullexposure.com/.

What the company looks like in a sentence

BiomX develops targeted phage treatments for bacterial indications and funds development with a blend of government contracts (notably U.S. defense health awards), foundation support, and capital raises; this hybrid funding model makes grant/contract continuity and access to capital the primary commercial levers for the business.

The partner map — every named relationship in recent reporting

Below are the external parties identified in recent public filings and press coverage, each summarized in plain English with source context.

H.C. Wainwright & Co.

H.C. Wainwright acted as the exclusive placement agent for a $3.0 million private placement and also serves as manager under an ATM agreement that gives BiomX the ability to issue shares up to a program size. According to a GlobeNewswire release on December 29, 2025 and a Globe and Mail press summary, Wainwright handled the December 2025 placement and is the manager on the ATM arrangement (FY2025).

Israeli Innovation Authority

BiomX reported decreased grant funding from the Israeli Innovation Authority during FY2025, reducing a historical non-dilutive funding stream that supported R&D activities. That decline was recounted in a Q3 2025 earnings call transcript covered by InsiderMonkey (FY2025).

Medical Technology Enterprise Consortium (MTEC)

MTEC is cited as both a funder and program manager in support of BiomX’s S. aureus program via an OTA; the company reported decreased grant funding from MTEC in FY2025 while still citing MTEC-managed awards in other disclosures. The change in grant flow was noted in the FY2025 call transcript (InsiderMonkey), and MTEC’s role in supporting DHA‑managed funding is described in a GlobeNewswire release (Nov 4, 2025).

Defense Health Agency (DHA)

The U.S. Defense Health Agency is a material funder: BiomX disclosed roughly $40 million of support to date from DHA‑managed programs for its phage development efforts, a crucial non-dilutive contributor to operations (GlobeNewswire, Nov 4, 2025).

Department of the Navy

The Department of the Navy provided funding under an OTA award administered through MTEC, and BiomX identifies Navy‑managed programs as part of the ~$40 million non-dilutive support that has backed its S. aureus program (GlobeNewswire, Nov 4, 2025).

Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD)

NMRC/NAMD is named as the manager for the Navy‑sponsored OTA through MTEC, effectively administering the development award that funded BiomX’s program work (GlobeNewswire, Nov 4, 2025).

U.S. DHA (alternate mention)

BiomX’s releases reference the U.S. DHA again in connection with the cumulative ~$40 million of non‑dilutive funding supporting phage development programs (GlobeNewswire, Nov 4, 2025).

Continental Stock Transfer & Trust Company

Continental is BiomX’s transfer agent and was responsible for issuing instructions to holders about the one‑for‑nineteen reverse stock split that became effective in November 2025 (GlobeNewswire, Nov 14, 2025).

NYSE American

The company confirmed that common stock continues to trade on the NYSE American under the symbol PHGE and that trading would reflect the split adjustment on November 25, 2025, as covered in market notices and QuiverQuant’s Nov 2025 post (QuiverQuant; GlobeNewswire, Nov 2025).

Cystic Fibrosis Foundation

The CF Foundation is actively supporting BiomX’s programs through advisory engagement and other assistance; company remarks in a Q3 2025 earnings call explained the foundation’s operational and regulatory support role (InsiderMonkey, FY2025).

How these relationships shape the operating model

The publicly disclosed relationships and constraints point to a capital‑intensive, partnership‑dependent operational model:

  • Financing posture: BiomX maintains a formal ATM framework and executes discrete private placements (evidence: explicit ATM agreement and December 2025 placement with H.C. Wainwright). That gives the company recurring access to equity capital but also creates ongoing dilution risk tied to financing needs.
  • Short-term service contracting: Clinical and manufacturing relationships tend to be short‑term and renewable, which increases vendor turnover risk and operational friction when scaling trials or moving toward commercial manufacturing.
  • Heavy government counterparty exposure: Multiple citations of the DHA, Department of Navy, MTEC and Navy R&D units signal material dependence on government funding and program management; that funding has been critical (roughly $40M to date) to advancing programs.
  • Manufacturing and distribution are outsourced and material: BiomX relies on third‑party manufacturers, CROs, testing labs and logistics partners for development and trials; these service providers are operationally critical and their performance directly affects timelines and regulatory compliance.
  • Geographic/manufacturing stipulation: Licensing and award terms impose U.S. manufacturing requirements for licensed inventions or product uses in the United States, which raises manufacturing localization and scale considerations.

These constraints are company‑level signals drawn from disclosures and contract excerpts; the ATM evidence explicitly names the placement manager (H.C. Wainwright) and government licensing excerpts name U.S. research institutions.

For investors who track supplier and funding risk, a deeper contract review is warranted — if you want a consolidated view of counterparties and contract signals, explore further at https://nullexposure.com/.

Investment implications — what matters next

  • Primary value drivers are regulatory progress in lead indications, continued non‑dilutive funding execution, and the company’s ability to raise follow‑on capital without excessive dilution. BiomX’s reported market capitalization is small and cash runway depends on both grant continuity and access to capital markets.
  • Operational risk centers on outsourced manufacturing and short‑term service agreements; any interruption or failure by third‑party manufacturers/CROs would materially delay programs and force costly replacements.
  • Catalysts to watch: additional MTEC/DHA awards, FDA interactions referenced by management, and the successful execution of capital raises under the ATM or private placements.

For a concise, supplier‑focused report and alerts about counterparties and funding changes, visit https://nullexposure.com/.

Bottom line

BiomX is a pre‑revenue developer that depends on government awards, foundation support, and capital markets intermediation to fund clinical development; H.C. Wainwright, multiple U.S. defense health entities, MTEC/NMRC, and a handful of service providers are central to that model. Investors should treat grant and contract continuity plus third‑party manufacturing stability as the primary operational risks, and monitor ATM/private placement activity for dilution cues. For ongoing monitoring and supplier intelligence, return to https://nullexposure.com/.